We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, CVS Health (CVS - Free Report) closed at $87.85, marking a -1.44% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.77%. Meanwhile, the Dow lost 0.67%, and the Nasdaq, a tech-heavy index, lost 0.92%.
The drugstore chain and pharmacy benefits manager's stock has dropped by 4.22% in the past month, falling short of the Medical sector's loss of 3.65% and the S&P 500's gain of 0.96%.
Analysts and investors alike will be keeping a close eye on the performance of CVS Health in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.62, signifying a 1.25% increase compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $105.04 billion, reflecting a 2.11% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.02 per share and a revenue of $418.17 billion, signifying shifts of +18.81% and +4.01%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for CVS Health. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, CVS Health holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that CVS Health has a Forward P/E ratio of 11.11 right now. This represents a discount compared to its industry average Forward P/E of 17.04.
We can also see that CVS currently has a PEG ratio of 0.87. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.61.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
CVS Health (CVS) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, CVS Health (CVS - Free Report) closed at $87.85, marking a -1.44% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.77%. Meanwhile, the Dow lost 0.67%, and the Nasdaq, a tech-heavy index, lost 0.92%.
The drugstore chain and pharmacy benefits manager's stock has dropped by 4.22% in the past month, falling short of the Medical sector's loss of 3.65% and the S&P 500's gain of 0.96%.
Analysts and investors alike will be keeping a close eye on the performance of CVS Health in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.62, signifying a 1.25% increase compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $105.04 billion, reflecting a 2.11% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.02 per share and a revenue of $418.17 billion, signifying shifts of +18.81% and +4.01%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for CVS Health. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. As of now, CVS Health holds a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that CVS Health has a Forward P/E ratio of 11.11 right now. This represents a discount compared to its industry average Forward P/E of 17.04.
We can also see that CVS currently has a PEG ratio of 0.87. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.61.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.